Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

I-131-Apamistamab - Actinium Pharmaceuticals

Next Previous
Drug Profile

I-131-Apamistamab - Actinium Pharmaceuticals

Alternative Names: 131-I-labeled anti-CD45 antibody; 131-I-labeled BC8 antibody; 131I-BC8 (anti-CD45) antibody - Actinium Pharmaceuticals; Anti-CD45 monoclonal antibody-BC8-I-131; Anti-CD45 monoclonal antibody-I-131; BC 8; BC8-I-131 construct; I-131-BC8; I131-Apamistamab; Iodine I 131 Apamistamab; Iodine-131-apamistamab; Iomab-ACT; Iomab-B

Latest Information Update: 04 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Actinium Pharmaceuticals; Fred Hutchinson Cancer Research Center; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Immunoconjugates; Iodine radioisotopes; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Diffuse large B cell lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 04 Apr 2024 Actinium Pharmaceuticals announces intention to submit MAA to European Medicines Agency for Acute myeloid leukemia in 2024 and anticipates approval in 2025
  • 03 Apr 2024 Actinium Pharmaceuticals plans a clinical trial of I-131 apamistamab as a targeted conditioning agent prior to CAR T-cell therapy
  • 28 Mar 2024 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Combination therapy, In the elderly, Second-line therapy or greater, In adults) in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top